Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
FCF to Net Income | 59.3% | 69.1% | 79.7% | (0.3%) | (4.8%) | 41.2% | 98.8% | 44.9% | 68.6% | 57.6% | 55.7% | 84.5% | 34.3% | 87.9% | 88.9% | 99.6% | 86.1% | 50.0% | 75.0% | 69.9% |
Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.
As of today, Microsoft Corp's last 12-month FCF to Net Income is 64.4%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual FCF to Net Income for West Pharmaceutical Services, Inc. have been 65.4% over the past three years, and 76.9% over the past five years.
As of today, West Pharmaceutical Services, Inc.'s FCF to Net Income is 64.4%, which is lower than industry median of 77.5%. It indicates that West Pharmaceutical Services, Inc.'s FCF to Net Income is Bad.